Drug Profile
Research programme: skin disease therapeutics - Unknown
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Unknown
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Skin-disorders in USA (Topical)
- 21 Mar 2017 An undisclosed comapny in-licenses Multiplexed molecular penetration enhancer technology from Crescita Therapeutics
- 21 Mar 2017 Crescita Therapeutics has patent protection for Multiplexed molecular penetration enhancer technology in USA